David R Strutton

Author PubWeight™ 9.95^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.	Clin Ther	2013	2.03
2	Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.	Vaccine	2010	1.23
3	Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.	Vaccine	2009	1.00
4	The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.	Clin Ther	2008	0.91
5	Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.	Vaccine	2009	0.87
6	Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.	BMC Infect Dis	2010	0.83
7	Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.	Expert Rev Vaccines	2012	0.83
8	Impact of smoking on respiratory illness-related outpatient visits among 50- to 75-year-olds in the United States.	Clin Ther	2002	0.79
9	Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.	BMC Infect Dis	2013	0.77
10	Letter to the editor.	Clin Ther	2013	0.75